Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data

Journal of Hypertension
Thomas D GilesHarold M Wright

Abstract

: To treat hypertension, combining two or more antihypertensive drugs from different classes is often necessary. β-Blockers and renin-angiotensin-aldosterone system inhibitors, when combined, have been deemed 'less effective' based on partially overlapping mechanisms of action and limited evidence. Recently, the single-pill combination (SPC) of nebivolol (Neb) 5 mg - a vasodilatory β1-selective antagonist/β3 agonist - and valsartan 80 mg, an angiotensin II receptor blocker, was US Food and Drug Administration-approved for hypertension. Pharmacological profiles of Neb and valsartan, alone and combined, are well characterized. In addition, a large 8-week randomized trial in stages I-II hypertensive patients (N = 4161) demonstrated greater blood pressure-reducing efficacy for Neb/valsartan SPCs than component monotherapies with comparable tolerability. In a biomarkers substudy (N = 805), Neb/valsartan SPCs prevented valsartan-induced increases in plasma renin, and a greater reduction in plasma aldosterone was observed with the highest SPC dose vs. valsartan 320 mg/day. This review summarizes preclinical and clinical evidence supporting Neb/valsartan as an efficacious and well tolerated combination treatment for hypertension.

References

Jun 1, 1991·Journal of Cardiovascular Pharmacology·Y S GaoP M Vanhoutte
Jan 1, 1988·Clinical and Experimental Hypertension. Part A, Theory and Practice·L M WingD O Southgate
Jan 1, 1996·European Journal of Clinical Pharmacology·A HimmelmannJ Hedner
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Feb 1, 2003·American Journal of Hypertension·Arnfried U KlingbeilRoland E Schmieder
Feb 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Scott M MacKenzieEleanor Davies
Apr 15, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Hanke MollnauThomas Münzel
Jun 14, 2003·TheScientificWorldJournal·Lourdes A FortepianiJoaquín García-Estañ
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Dec 12, 2003·Journal of Cardiovascular Pharmacology·Annemieke A de GrootStephan L M Peters
Nov 24, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Boris SchmidtBernhard Schieffer
May 4, 2005·Hypertension·Matthias SchmittJohn R Cockcroft
Dec 24, 2005·American Journal of Hypertension·Michael A Weber
Feb 14, 2006·British Journal of Pharmacology·Bertrand RozecChantal Gauthier
Apr 6, 2006·Circulation·Ulrich Förstermann, Thomas Münzel
May 9, 2006·Cardiology·Kurt StoschitzkyHarald Dobnig
Mar 14, 2007·Circulation·John E DeanfieldTon J Rabelink
Aug 2, 2007·Nature Reviews. Drug Discovery·Csaba SzabóRafael Radi
Aug 10, 2007·Current Hypertension Reports·Michala E Pedersen, John R Cockcroft
Aug 25, 2007·Nature Clinical Practice. Nephrology·Andrew S Bomback, Philip J Klemmer
Nov 22, 2007·Journal of Managed Care Pharmacy : JMCP·Steven A Atlas
Jan 15, 2008·Journal of Hypertension·Zahid DhakamIan B Wilkinson
May 12, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Xavier F FigueroaJ Pablo Huidobro-Toro
May 16, 2009·Therapeutic Advances in Cardiovascular Disease·Angelo Maffei, Giuseppe Lembo
Jul 17, 2009·Cardiovascular Therapeutics·Nikolaos TzemosThomas M MacDonald

❮ Previous
Next ❯

Citations

Nov 20, 2018·The Annals of Pharmacotherapy·Dawn BattiseDonald S Nuzum
May 9, 2019·Basic & Clinical Pharmacology & Toxicology·Nasima OlawiMarkus Wehland
Oct 17, 2020·Future Cardiology·Sarah J Wang, Gary E Sander
Jan 22, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wu-Wen FengJia-Bo Wang

❮ Previous
Next ❯

Software Mentioned

COSMOS

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.